AMRX Q1 2023 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q1 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$558M+12.0% YoY

Gross Profit

$178M32.0% margin

Operating Income

$34M6.2% margin

Net Income

-$7M-1.2% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

-8.6%

Cash Flow

Operating Cash Flow

$140M

Free Cash Flow

$128M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$3.6B

Total Liabilities

$3.5B

Stockholders' Equity

$294M

Cash & Equivalents

$145M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$558M	$498M	+12.0%
Gross Profit	$178M	$175M	+2.1%
Operating Income	$34M	$23M	+47.8%
Net Income	-$7M	-$2M	-222.0%

Revenue Segments

Generics Segment

$344M62%

Av K A R E Segment

$122M22%

Amneal Specialty Pharma Segment

$92M16%